Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics

European Psychiatry

Volumn 13, Issue 6, 1998, Pages 310-314

  Bech, P ^a   Peuskens, J C J R ^b   Marder, S R ^c   Chouinard, G ^d   Hoyberg O J ^e   Huttunen, M O ^h   Blin, O ^f   Claus, A ^g  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^e Molde Hospital   (Norway)

^f TIMONE HOSPITAL   (France)

^g Univ Psychiat Hosp St Camillus   (Belgium)

^h NONE

Author keywords

Efficacy; Meta analysis schizophrenia; Risperidone; Tolerability

Indexed keywords

ANTIPARKINSON AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0032172356     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(98)80049-7     Document Type: Article

References (26)

1. 1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev (DSM-III-R). Washington: American Psychiatric Association; 1987
2. 2 Andreasen NC, Olsen SA. Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982 ; 39 : 789-94
3. 3 Bech P, Cialdella P. Citalopram in depression: meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992 ; 6 suppl 5 : 45-54
4. 4 Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and levomepromazine in schizophrenic patients. J Clin Psychopharmacol 1996 ; 16 : 38-44
5. 5 Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992 ; 28 : 213-8
6. 6 Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychophannacol 1995 ; 10 : 207-13
7. 7 Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980 ; 7 : 233
8. 8 Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993 ; 13 : 25-40
9. 9 Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992 ; 85 : 295-305
10. 10 Cohen J. Statistical Power Analysis for the Behavioral Sciences. Orlando: Academic Press; 1977
11. 11 Davis JM, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic. Psychiatr Ann 1996 ; 26 : 78-87
12. 12 Glass GV. Integrating findings: the meta-analysis of research. Rev Educ Res 1977 ; 5 : 351-79
13. 13 Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994 ; 192 : 547-51
14. 14 Guy W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual. Rockville: National Institute of Mental Health; 1976
15. 15 Høyberg OJ, Fensbo C. Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 1993 ; 88 : 395-402
16. 16 Huttunen MO, Pieponnen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995 ; 91 : 271-7
17. 17 Kane JM. Risperidone. Am J Psychiatry 1994 ; 151 : 802-3
18. 18 Kane J, Honigfeld G, Singer J, Meltzer H. Ciozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with haloperidol. Arch Gen Psychiatry 1988 ; 45 : 789-96
19. 19 Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261-76
20. 20 Leysen JE, Gommeren W, Eens A. De Chaffoy de Courcelles D, Stoof JC, Janssen PAJ. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988 ; 247 : 661-70
21. 21 Lieberman JA, Johns CA, Kane JM, Rai K. Clozapine-induced agranulocytosis: non-cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988 ; 49 : 271-7
22. 22 Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994 ; 151 : 825-35
23. 23 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 pKi values. J Pharmacol Exp Ther 1989 ; 251 : 238-49
24. 24 Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995 ; 245 : 45-9
25. 25 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962 ; 10 : 799-812
26. 26 Peuskens J, the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995 ; 166 : 712-26